ERBB2 and breast cancer: Although anti-HER2 therapy together with operation and chemotherapy contribute to a favorable clinical outcome of HER2+ BC patients, around 10% HER2+ patients still suffer recurrence or metastasis with the reasons unknown (DeSantis et al., 2019).